title: Are Accurins the cure for Aurora kinase inhibitors?
abstract: A nanoparticle formulation of an Aurora B inhibitor increases antitumor efficacy and reduces toxicity, which may be a precedent for the use of this technology with other small molecules (Ashton et al., this issue).
authors: Tolero Pharmaceuticals, 2975 W. Executive Parkway, Suite 320, Lehi, UT 84043, USA. E-mail: dbearss@toleropharma.com.
authors: David J
authors: DJ
authors: Bearss
mesh_terms: D064096:Aurora Kinase A; D064107:Aurora Kinase B; D064127:Aurora Kinases; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D047428:Protein Kinase Inhibitors; D064096:Aurora Kinase A; D064107:Aurora Kinase B; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases